Dissecting pathomechanisms and therapeutic responses of steatotic liver disease using primary mouse liver and blood cells in a liver-on-a-chip model
Liu, H., Yin, G., Kohlhepp, M.S., Schumacher, F., Hundertmark, J., Abdelwahab Hassan, M., Heymann, F., Puengel, T., Kleuser, B., Mosig, A.S., Tacke, F., Guillot, A. (2024). Advanced Science ·
DOI ↗Uses a liver-on-a-chip with primary liver and blood cells to dissect the mechanisms and treatment responses of steatotic liver disease.
Repression of HNF4A enables transcriptomic reprogramming during the hepatic acute-phase response
Ehle, C., Iyer-Bierhoff, A., Wu, Y., Xing, S., Kiehntopf, M., Mosig, A.S., Godmann, M., Heinzel, T. (2024). Communications Biology ·
DOI ↗Reveals how repression of the transcription factor HNF4A reprograms hepatocytes during the liver's acute-phase response to inflammation.
An organ-on-chip platform for simulating drug metabolism along the gut-liver axis
Lucchetti, M., Kehinde Oluwasegun, A., Grandmougin, L., Jäger, C., Perez-Escriva, P., Letellier, E., Mosig, A.S., Wilmes, P. (2024). Advanced Healthcare Materials ·
DOI ↗Couples gut and liver tissues on a single chip to reproduce drug metabolism along the gut-liver axis.
Functional integration of natural killer cells in a microfluidically perfused liver-on-a-chip model
Fahrner, R., Gröger, M., Settmacher, U., Mosig, A.S. (2023). BMC Research Notes ·
DOI ↗Integrates natural killer cells into a perfused liver-on-a-chip, adding innate lymphoid immunity to the model.
Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
Kaden, T., Graf, K., Rennert, K., Li, R., Mosig, A.S., Raasch, M. (2023). Scientific Reports ·
DOI ↗Assesses the liver toxicity of the antibiotics trovafloxacin and levofloxacin in a human microphysiological liver model.
Human macrophage polarization determines bacterial persistence of Staphylococcus aureus in a liver-on-chip-based infection model
Siwczak, F., Cseresnyes, Z., Hassan, M.I.A., Aina, K.O., Carlstedt, S., Sigmund, A., Gröger, M., Surewaard, B.G.J., Werz, O., Figge, M.T., Tuchscherr, L., Löffler, B., Mosig, A.S. (2022). Biomaterials ·
DOI ↗Shows in a liver-on-chip infection model that the polarization state of macrophages decides whether Staphylococcus aureus persists in liver tissue.
Studying metabolism with multi-organ chips, new tools for disease modelling, pharmacokinetics and pharmacodynamics
Shroff, T., Aina, K., Maass, C., Cipriano, M., Lambrecht, J., Tacke, F., Mosig, A.S., Loskill, P. (2022). Open Biology ·
DOI ↗Reviews how multi-organ chips study metabolism, supporting disease modelling and the pharmacokinetics and pharmacodynamics of drugs.
Emulating the gut-liver axis, dissecting the microbiome’s effect on drug metabolism using multiorgan-on-chip models
Lucchetti, M., Kaminska, M., Oluwasegun, A.K., Mosig, A.S., Wilmes, P. (2021). Current Opinion in Endocrine and Metabolic Research ·
DOI ↗Reviews how multi-organ-on-chip models emulate the gut-liver axis to dissect the microbiome's effect on drug metabolism.
CAAP48, a new sepsis biomarker, induces hepatic dysfunction in an in vitro liver-on-chip model
Blaurock-Möller, N., Gröger, M., Siwczak, F., Dinger, J., Schmerler, D., Mosig, A.S.*, Kiehntopf, M.* (2019). Frontiers in Immunology ·
DOI ↗Uses a liver-on-chip to show that the sepsis biomarker CAAP48 induces hepatic dysfunction.
Microphysiological systems meet hiPSC technology, new tools for disease modeling of liver infections in basic research and drug development
Raasch, M., Fritsche, E., Kurtz, A., Bauer, M., Mosig, A.S. (2019). Advanced Drug Delivery Reviews ·
DOI ↗Reviews how microphysiological systems combined with hiPSC technology enable modelling of liver infections for research and drug development.
Preservation of cell structure, metabolism, and biotransformation activity of liver-on-chip organ models by hypothermic storage
Gröger, M., Dinger, J., Kiehntopf, M., Peters, F.T., Rauen, U., Mosig, A.S. (2018). Advanced Healthcare Materials ·
DOI ↗Shows that hypothermic storage preserves the structure, metabolism and biotransformation activity of liver-on-chip models.
Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance
Mann, A., Pelz, T., Rennert, K., Mosig, A.S., Decker, M., Lupp, A. (2017). Human Cell ·
DOI ↗Evaluates HepaRG liver cells for detecting indirect drug-induced liver toxicity, using isoniazid as a model substance.
Monocyte-induced recovery of inflammation-associated hepatocellular dysfunction in a biochip-based human liver model
Gröger, M., Rennert, K., Giszas, B., Weiß, E., Dinger, J., Funke, H., Kiehntopf, M., Peters, F.T., Lupp, A., Bauer, M., Claus, R.A., Huber, O., Mosig, A.S. (2016). Scientific Reports ·
DOI ↗Shows in a biochip-based human liver model that monocytes help restore hepatocellular function after inflammation.
A human macrophage-hepatocyte co-culture model for comparative studies of infection and replication of Francisella tularensis LVS strain and subspecies holarctica and mediasiatica
Rennert, K., Otto, P., Funke, H., Huber, O., Tomaso, H., Mosig, A.S. (2016). BMC Microbiology ·
DOI ↗A human macrophage-hepatocyte co-culture used to compare infection and replication of different Francisella tularensis strains.
A microfluidically perfused three-dimensional human liver model
Rennert, K., Steinborn, S., Gröger, M., Ungerböck, B., Jank, A.M., Ehgartner, J., Nietzsche, S., Dinger, J., Kiehntopf, M., Funke, H., Peters, F.T., Lupp, A., Gärtner, C., Mayr, T., Bauer, M., Huber, O., Mosig, A.S. (2015). Biomaterials ·
DOI ↗Introduces the microfluidically perfused three-dimensional human liver model that underpins the group's liver-on-chip work.